European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in
Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic
Factors for Treatment-Free Remission

J 2024

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS et. al.

Základní údaje

Originální název

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Autoři

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER (203 Česká republika, domácí), Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER a Susanne SAUSSELE

Vydání

Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 45.300 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1200/JCO.23.01647

UT WoS

001279720300007

Klíčová slova anglicky

Chronic Myeloid Leukemia; EURO-SKI

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 8. 2024 12:06, Mgr. Tereza Miškechová

Anotace

V originále

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Citovat

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER, Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER a Susanne SAUSSELE. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, roč. 42, č. 16, s. 1-11. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.01647.

@article{2423182,
   author = {Mahon, FrancoisandXavier and Pfirrmann, Markus and Dulucq, Stephanie and Hochhaus, Andreas and Panayiotidis, Panayiotis and Almeida, Antonio and Mayer, Jiří and HjorthandHansen, Henrik and Janssen, Jeroen J W M and Mustjoki, Satu and MartinezandLopez, Joaquin and Vestergaard, Hanne and Ehrencrona, Hans and Polakova, Katerina Machova and OlssonandStroemberg, Ulla and Ossenkoppele, Gert and Berger, Marc G and Etienne, Gabriel and Dengler, Jolanta and Bruemmendorf, Tim H and Burchert, Andreas and Rea, Delphine and Rousselot, Philippe and Nicolini, Franck E and Hofmann, WolfandKarsten and Richter, Johan and Saussele, Susanne},
   article_location = {PHILADELPHIA},
   article_number = {16},
   doi = {http://dx.doi.org/10.1200/JCO.23.01647},
   keywords = {Chronic Myeloid Leukemia; EURO-SKI},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of clinical oncology},
   title = {European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission},
   url = {https://ascopubs.org/doi/10.1200/JCO.23.01647},
   volume = {42},
   year = {2024}
}

TY  - JOUR
ID  - 2423182
AU  - Mahon, Francois-Xavier - Pfirrmann, Markus - Dulucq, Stephanie - Hochhaus, Andreas - Panayiotidis, Panayiotis - Almeida, Antonio - Mayer, Jiří - Hjorth-Hansen, Henrik - Janssen, Jeroen J W M - Mustjoki, Satu - Martinez-Lopez, Joaquin - Vestergaard, Hanne - Ehrencrona, Hans - Polakova, Katerina Machova - Olsson-Stroemberg, Ulla - Ossenkoppele, Gert - Berger, Marc G - Etienne, Gabriel - Dengler, Jolanta - Bruemmendorf, Tim H - Burchert, Andreas - Rea, Delphine - Rousselot, Philippe - Nicolini, Franck E - Hofmann, Wolf-Karsten - Richter, Johan - Saussele, Susanne
PY  - 2024
TI  - European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
JF  - Journal of clinical oncology
VL  - 42
IS  - 16
SP  - 1-11
EP  - 1-11
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 0732183X
KW  - Chronic Myeloid Leukemia
KW  - EURO-SKI
UR  - https://ascopubs.org/doi/10.1200/JCO.23.01647
N2  - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
ER  -

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER, Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER a Susanne SAUSSELE. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. \textit{Journal of clinical oncology}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2024, roč.~42, č.~16, s.~1-11. ISSN~0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.01647.

Podrobný výpis o publikaci